Catalent, Inc. (NYSE:CTLT) is set to announce first quarter earning results on Tuesday 3rd November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, CTLT to report 1Q21 income of $ 0.36 per share.
For the full year, analysts anticipate top line of $ 3566.61 million, while looking forward to income of $ 2.38 per share bottom line.
The Company Outlook
Full Year 2021 topline are forecasted in a range of$ 3,450.00 million ~ $ 3,600.00 million, where as bottomline are predicted in a range of $ 2.19 ~ $ 2.42 per share
Click Here For More Historical Outlooks Of Catalent, Inc.
Previous Quarter Performance
Catalent, Inc. posted income for the fourth quarter of $ 0.90 per share, from the revenue of $ 947.60 million. The quarterly earnings 28.57 percent while revenues extended 30.58 percent compared with the same quarter last year.
According to street consensus, CTLT was expected to report 4Q20 income of $ 0.79 per share from revenue of $ 895.51 million. The bottom line results beat street analysts by $ 0.11 or 13.92 percent, at the same time, top line results outshined analysts by $ 52.09 million or 5.82 percent.
Stock Performance
Shares of Catalent, Inc. traded up $ 0.76 or 0.87 percent on Monday, reaching $ 88.53 with volume of 826.00 thousand shares. Catalent, Inc. has traded high as $ 90.13 and has cracked $ 87.16 on the downward trend
The closing price of $ 88.53, representing a 182.76 % increase from the 52 week low of $ 31.04 and a 8.93 % decrease over the 52 week high of $ 96.38.
The company has a market capital of $ 14.56 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Catalent, Inc. will be hosting a conference call at 8:15 AM eastern time on 3rd November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.catalent.com
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services.
